Esperion Therapeutics (ESPR) Stock Price Up 8.3%

Esperion Therapeutics Inc (NASDAQ:ESPR) rose 8.3% during mid-day trading on Thursday . The stock traded as high as $46.66 and last traded at $49.22. Approximately 387,975 shares were traded during trading, a decline of 53% from the average daily volume of 820,747 shares. The stock had previously closed at $45.43.

ESPR has been the subject of several research analyst reports. Stifel Nicolaus initiated coverage on shares of Esperion Therapeutics in a research report on Friday, September 14th. They set a “buy” rating and a $89.00 target price for the company. Citigroup upgraded shares of Esperion Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the company from $57.00 to $75.00 in a research report on Friday, August 17th. Zacks Investment Research raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating and set a $51.00 price target on the stock in a research note on Wednesday, October 3rd. BTIG Research assumed coverage on shares of Esperion Therapeutics in a research note on Tuesday, October 16th. They set a “buy” rating and a $82.00 price target on the stock. Finally, BidaskClub downgraded shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, September 22nd. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $75.96.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($1.86) EPS for the quarter, missing the consensus estimate of ($1.64) by ($0.22). During the same period in the previous year, the firm earned ($1.86) EPS. On average, research analysts forecast that Esperion Therapeutics Inc will post -6.31 EPS for the current year.

In related news, Director Roger S. Newton sold 7,300 shares of Esperion Therapeutics stock in a transaction on Friday, August 17th. The shares were sold at an average price of $50.06, for a total value of $365,438.00. Following the transaction, the director now directly owns 616,426 shares of the company’s stock, valued at $30,858,285.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Roger S. Newton sold 2,827 shares of Esperion Therapeutics stock in a transaction on Friday, November 2nd. The stock was sold at an average price of $50.07, for a total transaction of $141,547.89. Following the completion of the transaction, the director now directly owns 573,953 shares in the company, valued at $28,737,826.71. The disclosure for this sale can be found here. Insiders have sold 37,327 shares of company stock worth $1,885,665 over the last three months. Insiders own 32.50% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. BB Biotech AG increased its stake in shares of Esperion Therapeutics by 31.9% in the second quarter. BB Biotech AG now owns 3,182,964 shares of the biopharmaceutical company’s stock worth $124,740,000 after buying an additional 770,000 shares during the period. Meditor Group Ltd increased its stake in shares of Esperion Therapeutics by 1.6% in the second quarter. Meditor Group Ltd now owns 2,629,835 shares of the biopharmaceutical company’s stock worth $103,063,000 after buying an additional 40,600 shares during the period. Partner Fund Management L.P. increased its stake in shares of Esperion Therapeutics by 117.7% in the second quarter. Partner Fund Management L.P. now owns 2,460,157 shares of the biopharmaceutical company’s stock worth $96,414,000 after buying an additional 1,330,159 shares during the period. BlackRock Inc. increased its stake in shares of Esperion Therapeutics by 21.3% in the second quarter. BlackRock Inc. now owns 1,805,232 shares of the biopharmaceutical company’s stock worth $70,746,000 after buying an additional 316,635 shares during the period. Finally, Boxer Capital LLC increased its stake in shares of Esperion Therapeutics by 52.8% in the second quarter. Boxer Capital LLC now owns 1,375,000 shares of the biopharmaceutical company’s stock worth $53,886,000 after buying an additional 475,000 shares during the period.

Esperion Therapeutics Company Profile (NASDAQ:ESPR)

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Featured Article: What is a stock split?

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply